Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug without other medications, a federal judge ruled, finding the generic’s label won’t encourage doctors to prescribe it that way.

Chief Judge Colm F. Connolly granted a request for judgment by Viatris’ Mylan Pharmaceuticals Inc. unit in an opinion issued Tuesday in the US District Court for the District of Delaware, tossing Novo’s claims of direct, induced, and contributory infringement of US Patent No. 9,764,003, one of several asserted to block the generic version of Wegovy.

“Mylan’s proposed label does not ...